NuVasive’s Intriguing $380M+ Deal for Ellipse

article image

The sale of Ellipse Technologies to NuVasive in February for a whopping multiple demonstrated that an ultra-niche market can be attractive for a start-up. As for NuVasive, the deal offered a de-risked innovation in a tricky area of spine surgery, but implementing the company’s grand ambitions for its new asset poses challenges.

NuVasive Inc.’s acquisition of Ellipse Technologies in February for $380 million plus $30 million in sales milestones, casts a spotlight on an exceptionally intriguing, albeit ultra-niche, clinical need.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: